Stem cell therapy True or fiction Dr. Ahmed korie alexandria university
Stem cell therapy True or fiction Dr. Ahmed korie alexandria universityFrom:mansvuViews:2 0ratingsTime:29:49More inEducation
Read the original post:
Stem cell therapy True or fiction Dr. Ahmed korie alexandria university - Video
Stem Cell #39;s explained part 1 on The Susana Kennedy Show on 2oceansvibe
My ever increasing curiosity with the possibilities of Stem Cell therapy recently led me to meeting up with Dr. Duncan Carmichael from The Anti-Aging Clinic in Cape town, we chatted about what stem cell #39;s are, what some of the possibilities are and more, this is part one of a series of interviews I will be releasing over the next few weeks, demystifying the myths and revealing the incredible possibilities that are actually already available to you all right now. Enjoy!From:Susana KennedyViews:1 0ratingsTime:08:32More inScience Technology
Continue reading here:
Stem Cell's explained part 1 on The Susana Kennedy Show on 2oceansvibe - Video
NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--
BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed an agreement with Octane Biotech of Kingston, Ontario, to jointly develop a proprietary bioreactor for production of its NurOwn stem cell therapy candidate. The customized bioreactor will enable BrainStorm to optimize its NurOwn production process, significantly increasing its production capabilities by using a single clean room for multiple patients, reducing costs and time. The project is supported by a grant awarded by the Canada-Israel Industrial Research and Development Foundation (CIIRDF).
Under the terms of the agreement, the companies will develop a commercially viable, safe, reliable, and cost-effective bioreactor for scale-up of BrainStorms NurOwn stem cell therapy, using Octanes Automated Cell & Tissue Engineering System (ACTES) technology. The CIIRDF funding award was approved for a period of three years.
Octane is the ideal partner for us, since they have a particular expertise in developing automated production processes for mesenchymal cell therapy technologies, commented Dr. Adrian Harel, BrainStorms CEO. We are anxious to move ahead with this project, in order to be in a position to provide NurOwn as quickly as possible, and to as many patients as possible, in the near future.
The opportunity to work with BrainStorm on scaling-up the NurOwn production process is a particularly meaningful one, given the urgency of its target population, said Dr. Tim Smith, Octanes CEO. We are confident that our combined knowledge base and commitment to the project will help advance their product significantly closer to clinical use.
BrainStorm is currently conducting a Phase I/II clinical trial in ALS patients at the Hadassah Medical Center in Jerusalem and is planning to expand its clinical development in the USA, pending FDA approval. Towards that goal, the Company has entered into a Memorandum of Understanding with the University of Massachusetts Medical School and Massachusetts General Hospital to begin ALS human clinical trials at these institutions.
About BrainStorm Cell Therapeutics
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the companys website at http://www.brainstorm-cell.com.
About Octane Biotech
Octane develops innovative bioreactor-based systems to meet the production challenges inherent in the progressive scale-up of manual cell culture protocols. The companys unique Automated Cell & Tissue Engineering System (ACTES) solution integrates state-of-the-art bioreactors, biosensors and bioprocessing to enable routine GMP production of cell-based products for clinical therapeutics. Octane Biotech Inc. is one of three affiliated companies within the Octane Medical Group. For more information, visit the companys website at http://www.octaneco.com.
Continued here:
BrainStorm and Octane to Develop Revolutionary Bioreactor-Based NurOwn Stem Cells Production Process
Stem cells and Diabetes
Song- I remember, by Deadmau5 KaskadeFrom:mastercheef524Views:0 0ratingsTime:01:06More inPeople Blogs
More here:
Stem cells and Diabetes - Video
Stem Cells Research Commercial
For this biology project we had to choose a side on whether if we were for or against putting a stem cell research facility in our home town. We were for the cause and this is our commercial which is supposed to persuade the viewer to vote yes to the fictional #39;question 6 #39;.From:iamtrroyViews:0 0ratingsTime:02:01More inPeople Blogs
Originally posted here:
Stem Cells Research Commercial - Video
Stem cells and desensitization in renal transplantation. Prof. Gamal saadi. Cairo University
Stem cells and desensitization in renal transplantation. Prof. Gamal saadi. Cairo UniversityFrom:mansvuViews:2 0ratingsTime:29:32More inEducation
Follow this link:
Stem cells and desensitization in renal transplantation. Prof. Gamal saadi. Cairo University - Video
Stem cells and renal regeneration Dr. Amal Ibrahim. Alazhar university
Stem cells and renal regeneration Dr. Amal Ibrahim. Alazhar universityFrom:mansvuViews:2 0ratingsTime:09:50More inEducation
See the rest here:
Stem cells and renal regeneration Dr. Amal Ibrahim. Alazhar university - Video
Stem cells in clinical trials. Prof. Hala ElWakil. Alexandria University
Stem cells in clinical trials. Prof. Hala ElWakil. Alexandria UniversityFrom:mansvuViews:1 0ratingsTime:27:12More inEducation
Read the original post:
Stem cells in clinical trials. Prof. Hala ElWakil. Alexandria University - Video
Stem cells therpy in Urology. Prof. yasser Osman. mansoura University
Stem cells therpy in Urology. Prof. yasser Osman. mansoura UniversityFrom:mansvuViews:1 0ratingsTime:25:36More inEducation
More:
Stem cells therpy in Urology. Prof. yasser Osman. mansoura University - Video
Stem cells migrating on the aligned fibers
Stem cells spreading on aligned electrospun nanofibersFrom:shaoping zhongViews:0 0ratingsTime:00:15More inPeople Blogs
See original here:
Stem cells migrating on the aligned fibers - Video
Stem cells attached and spread onto the aligned fibers
From:shaoping zhongViews:0 0ratingsTime:00:12More inPeople Blogs
Read the original post:
Stem cells attached and spread onto the aligned fibers - Video
Stem Cells Technology
The science of stem cells Dr. Nathan Newman, a world-renowned dermatologist and cosmetic surgeon, began searching for a topical treatment to help patients recovering from burns and severe injuries. Knowing that stem cells drive cell growth and regeneration, he isolated the stem cell growth factors that serve as the "language" communicating cellular activity. Although other scientists were using plant-based growth factors, Dr. Newman derived his growth factors from the stem cells of healthy adults, theorizing that cell communication in the same "language" would be more effective. The power behind LUMINESCE trade; The results were remarkable. And his 200+ growth factor complex is what you #39;ll experience in LUMINESCE trade; products from Jeunesse. This potent growth factor complex is able to rejuvenate skin cells faster and at a molecular level. New cell production is stimulated, resulting in increased collagen and elastin for firmer skin tone. New cells also give your complexion a fuller appearance with a healthy, vibrant glow. With LUMINESCE trade;, skin appears younger, because at the cellular level, it literally is younger.From:Mark CyrzanViews:0 0ratingsTime:03:36More inScience Technology
Read more:
Stem Cells Technology - Video
"Study of Human Neural Stem Cells in Thoracic Spinal Cord Injury" - Stephen Huhn, MD
Dr. Huhn, who is Vice President, Head of the CNS Program at Stem Cells, Inc., provides an update on the company #39;s clinical trial.From:unite2fightparalysisViews:0 0ratingsTime:23:03More inNonprofits Activism
Read more:
"Study of Human Neural Stem Cells in Thoracic Spinal Cord Injury" - Stephen Huhn, MD - Video
Stem Cells En Mpg4
Stem cell technology is a rapidly developing field that combines the efforts of cell biologists, geneticists, and clinicians and offers hope of effective treatment for a variety of malignant and non-malignant diseases.From:Kasia SowackiViews:0 0ratingsTime:03:36More inScience Technology
View original post here:
Stem Cells En Mpg4 - Video
For other things, however, the people around you have such high expectations you'll do them that you only lose points if you don't but gain very little if you do. For you, this may be true of the dishes. Certainly I've always maintained this is true for Valentine's Day. Get flowers and you simply maintain the relationship's status quo; fail to do anything and you lose big points fast.
As I conclude my article I will conclude here:
"In order to create the kinds of perceptions and solicit the kinds of actions we want from the world around us, we must engage the world around us. The world around us is engaging online.
For all kinds of selfish and selfless reasons you, your company or organization and your career will benefit from you engaging there too."
and this prediction:
"...in less than the blink it took for the commercial world to accept websites and email, it will seem similarly ridiculous for professionals, academics and companies to operate and succeed without actively using social media."
____________
If this topic is of interest to you, here are some great resources particularly focused on the value of social media to those in life sciences.
Canaday, M. Is Life Science Social Media Worth It Yet? Three Tenets Behind Its Relevance To Your Business. Comprendia. 6 December 2012.
Bersenev A. Scientific blogging as a model for professional networking online. Cellular Therapy and Transplantation. 2010;2(7). 10.3205/ctt-2010-en-000084.01.
Bersenev, A. Scientific blogging as a model for professional networking online. 4 August 2010. StemCellAssays.com
Bersenev, A. Who’s Who in the Stem Cell Blogosophere. 27 June 2011. StemCellAssays.com
Bishop, D. How to bury your academic writing. Bishop’s Blog. 26 August 2012.
Buckler, L. Don’t feel the pain of ignoring social media? Just wait a minute…. CellTherapyBlog.com 22 October 2008.
Jewell, T. Survey: How our scientists use social media. AZHealthConnections.com. 12 February 2012.
Knoepfer, P. Top ten tips for blogging for scientists. 2 August 2012. IPScell.com
Shipman, M. Why Scientists Should Publicize Their Findings – for Purely Selfish Reasons. Scientific America. Blog. 18 June 2012.
Shipman, M. A gentle introduction to Twitter for the apprehensive academic. Scientific America. Blog. 14 June 2011.
Small, G. Time to Tweet. Nature 2011. 479 141 2 November 2011
Wilcox, C. Social Media for Scientists Part 1: It’s Our Job. Scientific American Blog. 27 September 2011.
Wilcox, C. Social Media for Scientists Part 2: You Do Have time. Scientific American Blog. 29 September 2011.
Wilcox, C. Social Media for Scientists Part 3: Win-Win. Scientific American Blog. 10 October 2011.
Wilcox, C. Guest Editorial: It’s time to e-Volve. Taking Responsibility for Science Communication in a Digital Age. Biol Bull. 22285-87. (April 2012)
The Rules of Social Media. Fast Company. 8 August 2012.
Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/k7ANTnLXNjc/the-roi-on-pant-wearing-and-other.html
I welcome comments and feedback.
1. In addition to helping patients distinguish between compliant and non-compliant treatments (and providers) we must do more to help patients distinguish between non-compliant cell therapy treatments (and providers) which are more or less risky.
2. Whatever we do in response to this issue should be done with an eye to being practical and helpful to patients in the real-life context of their decision about whether or not to buy a non-complaint cell therapy.
3. Our response to this issue should be based on a risk-based approach recognizing that not all non-compliance is created equal. We should create a framework for risk-based analysis (both for us and our audiences) and focus initiatives around those which present the highest risk.
4. We recognize the problem of non-compliant cell therapies is not just a problem that exists in jurisdictions with little, no, or poor regulation but that is a growing problem even in the most highly regulated jurisdictions meaning the solution cannot be regulated it depends on education and enforcement.
5. We recognize regulatory agencies cannot enforce non-compliance on their own. We as an industry need to complement their efforts through our own standards and enforcement.
6. Stakeholder groups should support the formation of a multi-organizational initiative to, based on a risk-based assessment, spotlight the categories or signs of highest-risk offenders for use by patients and/or their physicians in identifying whether or not treatments (and providers) they may be considering fall into the that category associated with the highest level of risk.
What do you think?
Two other major California newspapers
today said the $3 billion California stem cell agency needs to “clean
up its act” if it wants to be successful in continuing its efforts
at turning stem cells into cures.
“The $700,000 spent on the
study...will be wasted if the institute's oversight board fails to
heed the (IOM) committee's
criticisms, which echo the findings of the Little Hoover
Commission and other groups over the years.”
“The 29-member board is made up
almost entirely of representatives of advocacy groups and research
institutions that have a direct interest in how the money is spent.”
“The board also overrode the advice
of its scientific advisors — twice on a single application when it
considered a grant for a well-connected company, StemCells Inc. based
in Newark, Calif. The board granted the company $20 million after Robert Klein, the driving force behind the passage of Proposition 71,
which created and funded the agency in 2004, and its former head,
lobbied so intensively for the company that one board member
described it as 'arm-twisting.'"
“The agency has used more than half
of its funding and one day will almost certainly want to ask
taxpayers for more. It should remember that voters will look for
evidence of public accountability as well as respected research.”
“(I)f it wants to survive...it
should heed the Institute of Medicine's advice to eliminate conflicts
of interest on its board -- and do it before awarding the remaining
$1.2 billion of the $3 billion voters approved for stem cell
research.”
“Long-term funding was never the
intent when Proposition 71 passed in 2004. It was supposed to
kick-start research at a time when federal funding was blocked and to
establish California as a major player in the rapidly advancing
medical field.
“The agency could continue to bring
value to the state as an advocate and funder of research, but only if
it can attract private donors, partners and investors. For that to
happen, it will need a board that passes the ethics test, with more
independent experts and industry executives free of conflicts.
“At the outset, stem cell advocates
took immense pride in structuring the agency to keep it relatively
free of legislative interference despite the use of public money.
Politicians kept their hands off, which was good. But the agency
created its own inappropriate influences in the way it constituted
its board. Now it needs to clean up its act.“
Mainstream news coverage today was skimpy, to put it mildly, of the testy session yesterday involving the governing board of the California stem
cell agency and representatives of the prestigious Institute of
Medicine(IOM).
"'I'm a
colon cancer survivor,' said Art Torres, vice chairman of the
oversight committee, and a patient advocate designate. 'Does having
colon cancer make me biased?'
“Jeff
Sheehy, another patient advocate designate, protested what he called
a 'defenestration' of patient advocates, whose interests often span
multiple diseases.”
Jon Shestack, a patient advocate member
of the governing board of the California stem cell agency, weighed in
today on the virtues of the grant application appeal process at the
$3 billion research enterprise.
The headline on the Los Angeles
Times web site this afternoon read,
"Is California's stem cell program
preparing to waste $700,000?"
"If you're betting that
the California
stem cell agency will spurn key recommendations of a
blue-ribbon review panel that criticized its leadership and
management structures, you might want to double that bet. Several
board members showed overt hostility to the panel's recommendations
during a public meeting today."
"CIRM Chairman Jonathan
Thomas glided over those issues when he introduced Shapiro.
Thomas observed that the Institute of Medicine report included many
statements "validating CIRM, its process, what it was able to
achieve," which is a bit like launching the investigation of a
plane crash by focusing on all the planes that land safely every day.
Thomas did mention that the Institute of Medicine had made numerous
recommendation about how to "take something which is already a
great experience and improve it even further."
"Shapiro got only a few minutes
into his presentation before board members started interrupting him
with objections to the Institute of Medicine's recommendation for a
majority of independent members."
"Thomas promised to stage a public
workshop on the Institute of Medicine report soon and to subject them
to 'lengthy discussion.'
"Does that sound as if the board
will be taking seriously the advice that it change the way it does
business? Stay tuned, but don't hold your breath."
Source:
Source:
Source:
Source: